Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART

Barbara Ensoli, Stefania Bellino, Antonella Tripiciano, Olimpia Longo, Vittorio Francavilla, Simone Marcotullio, Aurelio Cafaro, Orietta Picconi, Giovanni Paniccia, Arianna Scoglio, Angela Arancio, Cristina Ariola, Maria J. Ruiz Alvarez, Massimo Campagna, Donato Scaramuzzi, Cristina Iori, Roberto Esposito, Cristina Mussini, Florio Ghinelli, Laura Sighinolfi & 19 others Guido Palamara, Alessandra Latini, Gioacchino Angarano, Nicoletta Ladisa, Fabrizio Soscia, Vito S. Mercurio, Adriano Lazzarin, Giuseppe Tambussi, Raffaele Visintini, Francesco Mazzotta, Massimo Di Pietro, Massimo Galli, Stefano Rusconi, Giampiero Carosi, Carlo Torti, Giovanni Di Perri, Stefano Bonora, Fabrizio Ensoli, Enrico Garaci

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservoirs and to cell activation. Of note, in CD4+ T cells and monocyte-macrophages of virologically-suppressed individuals, there is continued expression of multi-spliced transcripts encoding HIV regulatory proteins. Among them, Tat is essential for virus gene expression and replication, either in primary infection or for virus reactivation during HAART, when Tat is expressed, released extracellularly and exerts, on both the virus and the immune system, effects that contribute to disease maintenance. Here we report results of an ad hoc exploratory interim analysis (up to 48 weeks) on 87 virologically-suppressed HAART-treated individuals enrolled in a phase II randomized open-label multicentric clinical trial of therapeutic immunization with Tat (ISS T-002). Eighty-eight virologically-suppressed HAART-treated individuals, enrolled in a parallel prospective observational study at the same sites (ISS OBS T-002), served for intergroup comparison. Immunization with Tat was safe, induced durable immune responses, and modified the pattern of CD4+ and CD8+ cellular activation (CD38 and HLA-DR) together with reduction of biochemical activation markers and persistent increases of regulatory T cells. This was accompanied by a progressive increment of CD4+ T cells and B cells with reduction of CD8+ T cells and NK cells, which were independent from the type of antiretroviral regimen. Increase in central and effector memory and reduction in terminally-differentiated effector memory CD4+ and CD8+ T cells were accompanied by increases of CD4+ and CD8+ T cell responses against Env and recall antigens. Of note, more immune-compromised individuals experienced greater therapeutic effects. In contrast, these changes were opposite, absent or partial in the OBS population. These findings support the use of Tat immunization to intensify HAART efficacy and to restore immune homeostasis.

Original languageEnglish
Article numbere13540
JournalPLoS One
Volume5
Issue number11
DOIs
Publication statusPublished - 2010

Fingerprint

Immunization
T-cells
Highly Active Antiretroviral Therapy
immunization
T-lymphocytes
Chemical activation
T-Lymphocytes
Viruses
therapeutics
viruses
cells
Homeostasis
homeostasis
env Gene Products
Human Immunodeficiency Virus Proteins
Therapeutics
Essential Genes
Data storage equipment
HLA-DR Antigens
Therapeutic Uses

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART. / Ensoli, Barbara; Bellino, Stefania; Tripiciano, Antonella; Longo, Olimpia; Francavilla, Vittorio; Marcotullio, Simone; Cafaro, Aurelio; Picconi, Orietta; Paniccia, Giovanni; Scoglio, Arianna; Arancio, Angela; Ariola, Cristina; Ruiz Alvarez, Maria J.; Campagna, Massimo; Scaramuzzi, Donato; Iori, Cristina; Esposito, Roberto; Mussini, Cristina; Ghinelli, Florio; Sighinolfi, Laura; Palamara, Guido; Latini, Alessandra; Angarano, Gioacchino; Ladisa, Nicoletta; Soscia, Fabrizio; Mercurio, Vito S.; Lazzarin, Adriano; Tambussi, Giuseppe; Visintini, Raffaele; Mazzotta, Francesco; Di Pietro, Massimo; Galli, Massimo; Rusconi, Stefano; Carosi, Giampiero; Torti, Carlo; Di Perri, Giovanni; Bonora, Stefano; Ensoli, Fabrizio; Garaci, Enrico.

In: PLoS One, Vol. 5, No. 11, e13540, 2010.

Research output: Contribution to journalArticle

Ensoli, B, Bellino, S, Tripiciano, A, Longo, O, Francavilla, V, Marcotullio, S, Cafaro, A, Picconi, O, Paniccia, G, Scoglio, A, Arancio, A, Ariola, C, Ruiz Alvarez, MJ, Campagna, M, Scaramuzzi, D, Iori, C, Esposito, R, Mussini, C, Ghinelli, F, Sighinolfi, L, Palamara, G, Latini, A, Angarano, G, Ladisa, N, Soscia, F, Mercurio, VS, Lazzarin, A, Tambussi, G, Visintini, R, Mazzotta, F, Di Pietro, M, Galli, M, Rusconi, S, Carosi, G, Torti, C, Di Perri, G, Bonora, S, Ensoli, F & Garaci, E 2010, 'Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART', PLoS One, vol. 5, no. 11, e13540. https://doi.org/10.1371/journal.pone.0013540
Ensoli, Barbara ; Bellino, Stefania ; Tripiciano, Antonella ; Longo, Olimpia ; Francavilla, Vittorio ; Marcotullio, Simone ; Cafaro, Aurelio ; Picconi, Orietta ; Paniccia, Giovanni ; Scoglio, Arianna ; Arancio, Angela ; Ariola, Cristina ; Ruiz Alvarez, Maria J. ; Campagna, Massimo ; Scaramuzzi, Donato ; Iori, Cristina ; Esposito, Roberto ; Mussini, Cristina ; Ghinelli, Florio ; Sighinolfi, Laura ; Palamara, Guido ; Latini, Alessandra ; Angarano, Gioacchino ; Ladisa, Nicoletta ; Soscia, Fabrizio ; Mercurio, Vito S. ; Lazzarin, Adriano ; Tambussi, Giuseppe ; Visintini, Raffaele ; Mazzotta, Francesco ; Di Pietro, Massimo ; Galli, Massimo ; Rusconi, Stefano ; Carosi, Giampiero ; Torti, Carlo ; Di Perri, Giovanni ; Bonora, Stefano ; Ensoli, Fabrizio ; Garaci, Enrico. / Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART. In: PLoS One. 2010 ; Vol. 5, No. 11.
@article{b16c26c3a60b4f8fb6abac69c2f2f507,
title = "Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART",
abstract = "Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservoirs and to cell activation. Of note, in CD4+ T cells and monocyte-macrophages of virologically-suppressed individuals, there is continued expression of multi-spliced transcripts encoding HIV regulatory proteins. Among them, Tat is essential for virus gene expression and replication, either in primary infection or for virus reactivation during HAART, when Tat is expressed, released extracellularly and exerts, on both the virus and the immune system, effects that contribute to disease maintenance. Here we report results of an ad hoc exploratory interim analysis (up to 48 weeks) on 87 virologically-suppressed HAART-treated individuals enrolled in a phase II randomized open-label multicentric clinical trial of therapeutic immunization with Tat (ISS T-002). Eighty-eight virologically-suppressed HAART-treated individuals, enrolled in a parallel prospective observational study at the same sites (ISS OBS T-002), served for intergroup comparison. Immunization with Tat was safe, induced durable immune responses, and modified the pattern of CD4+ and CD8+ cellular activation (CD38 and HLA-DR) together with reduction of biochemical activation markers and persistent increases of regulatory T cells. This was accompanied by a progressive increment of CD4+ T cells and B cells with reduction of CD8+ T cells and NK cells, which were independent from the type of antiretroviral regimen. Increase in central and effector memory and reduction in terminally-differentiated effector memory CD4+ and CD8+ T cells were accompanied by increases of CD4+ and CD8+ T cell responses against Env and recall antigens. Of note, more immune-compromised individuals experienced greater therapeutic effects. In contrast, these changes were opposite, absent or partial in the OBS population. These findings support the use of Tat immunization to intensify HAART efficacy and to restore immune homeostasis.",
author = "Barbara Ensoli and Stefania Bellino and Antonella Tripiciano and Olimpia Longo and Vittorio Francavilla and Simone Marcotullio and Aurelio Cafaro and Orietta Picconi and Giovanni Paniccia and Arianna Scoglio and Angela Arancio and Cristina Ariola and {Ruiz Alvarez}, {Maria J.} and Massimo Campagna and Donato Scaramuzzi and Cristina Iori and Roberto Esposito and Cristina Mussini and Florio Ghinelli and Laura Sighinolfi and Guido Palamara and Alessandra Latini and Gioacchino Angarano and Nicoletta Ladisa and Fabrizio Soscia and Mercurio, {Vito S.} and Adriano Lazzarin and Giuseppe Tambussi and Raffaele Visintini and Francesco Mazzotta and {Di Pietro}, Massimo and Massimo Galli and Stefano Rusconi and Giampiero Carosi and Carlo Torti and {Di Perri}, Giovanni and Stefano Bonora and Fabrizio Ensoli and Enrico Garaci",
year = "2010",
doi = "10.1371/journal.pone.0013540",
language = "English",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART

AU - Ensoli, Barbara

AU - Bellino, Stefania

AU - Tripiciano, Antonella

AU - Longo, Olimpia

AU - Francavilla, Vittorio

AU - Marcotullio, Simone

AU - Cafaro, Aurelio

AU - Picconi, Orietta

AU - Paniccia, Giovanni

AU - Scoglio, Arianna

AU - Arancio, Angela

AU - Ariola, Cristina

AU - Ruiz Alvarez, Maria J.

AU - Campagna, Massimo

AU - Scaramuzzi, Donato

AU - Iori, Cristina

AU - Esposito, Roberto

AU - Mussini, Cristina

AU - Ghinelli, Florio

AU - Sighinolfi, Laura

AU - Palamara, Guido

AU - Latini, Alessandra

AU - Angarano, Gioacchino

AU - Ladisa, Nicoletta

AU - Soscia, Fabrizio

AU - Mercurio, Vito S.

AU - Lazzarin, Adriano

AU - Tambussi, Giuseppe

AU - Visintini, Raffaele

AU - Mazzotta, Francesco

AU - Di Pietro, Massimo

AU - Galli, Massimo

AU - Rusconi, Stefano

AU - Carosi, Giampiero

AU - Torti, Carlo

AU - Di Perri, Giovanni

AU - Bonora, Stefano

AU - Ensoli, Fabrizio

AU - Garaci, Enrico

PY - 2010

Y1 - 2010

N2 - Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservoirs and to cell activation. Of note, in CD4+ T cells and monocyte-macrophages of virologically-suppressed individuals, there is continued expression of multi-spliced transcripts encoding HIV regulatory proteins. Among them, Tat is essential for virus gene expression and replication, either in primary infection or for virus reactivation during HAART, when Tat is expressed, released extracellularly and exerts, on both the virus and the immune system, effects that contribute to disease maintenance. Here we report results of an ad hoc exploratory interim analysis (up to 48 weeks) on 87 virologically-suppressed HAART-treated individuals enrolled in a phase II randomized open-label multicentric clinical trial of therapeutic immunization with Tat (ISS T-002). Eighty-eight virologically-suppressed HAART-treated individuals, enrolled in a parallel prospective observational study at the same sites (ISS OBS T-002), served for intergroup comparison. Immunization with Tat was safe, induced durable immune responses, and modified the pattern of CD4+ and CD8+ cellular activation (CD38 and HLA-DR) together with reduction of biochemical activation markers and persistent increases of regulatory T cells. This was accompanied by a progressive increment of CD4+ T cells and B cells with reduction of CD8+ T cells and NK cells, which were independent from the type of antiretroviral regimen. Increase in central and effector memory and reduction in terminally-differentiated effector memory CD4+ and CD8+ T cells were accompanied by increases of CD4+ and CD8+ T cell responses against Env and recall antigens. Of note, more immune-compromised individuals experienced greater therapeutic effects. In contrast, these changes were opposite, absent or partial in the OBS population. These findings support the use of Tat immunization to intensify HAART efficacy and to restore immune homeostasis.

AB - Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservoirs and to cell activation. Of note, in CD4+ T cells and monocyte-macrophages of virologically-suppressed individuals, there is continued expression of multi-spliced transcripts encoding HIV regulatory proteins. Among them, Tat is essential for virus gene expression and replication, either in primary infection or for virus reactivation during HAART, when Tat is expressed, released extracellularly and exerts, on both the virus and the immune system, effects that contribute to disease maintenance. Here we report results of an ad hoc exploratory interim analysis (up to 48 weeks) on 87 virologically-suppressed HAART-treated individuals enrolled in a phase II randomized open-label multicentric clinical trial of therapeutic immunization with Tat (ISS T-002). Eighty-eight virologically-suppressed HAART-treated individuals, enrolled in a parallel prospective observational study at the same sites (ISS OBS T-002), served for intergroup comparison. Immunization with Tat was safe, induced durable immune responses, and modified the pattern of CD4+ and CD8+ cellular activation (CD38 and HLA-DR) together with reduction of biochemical activation markers and persistent increases of regulatory T cells. This was accompanied by a progressive increment of CD4+ T cells and B cells with reduction of CD8+ T cells and NK cells, which were independent from the type of antiretroviral regimen. Increase in central and effector memory and reduction in terminally-differentiated effector memory CD4+ and CD8+ T cells were accompanied by increases of CD4+ and CD8+ T cell responses against Env and recall antigens. Of note, more immune-compromised individuals experienced greater therapeutic effects. In contrast, these changes were opposite, absent or partial in the OBS population. These findings support the use of Tat immunization to intensify HAART efficacy and to restore immune homeostasis.

UR - http://www.scopus.com/inward/record.url?scp=78649720290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649720290&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0013540

DO - 10.1371/journal.pone.0013540

M3 - Article

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e13540

ER -